NCT05486897|Completed
Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
PVWMH
Loading search results
PVWMH
Sponsor study identifier
observational
315
1 country
1
Study Start
September 5, 2022
Actual (reported)Primary Completion
December 15, 2023
Actual (reported)Study Completion
December 15, 2023
Actual (reported)White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). WMH tend to show a peri-basal ganglia pattern in HA, whereas a multiple subcortical spots pattern can be observed in CAA. Periventricular WMH (PVWMH) have been reported to be posterior predominant using a semiautomated segmentation method and logarithmic transformation, not used in daily clinical practice. In these studies including CAA patients, patients initially presented with haemorrhage-related symptoms. In another study analysing PVWMH and cerebral amyloid evidence in patients with mild cognitive impairment, frontal PVWMH burden was associated with high uptake on florbetapir-PET whereas parietal and occipital PVWMH burden was associated with low CSF-amyloid-beta. The aim of this study is the descriptive comparative analysis of the distribution of PVWMH between CAA and HA patients with radiological tools available in daily practice.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 15, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2, 2022
Actual (reported)August 4, 2022
Actual (reported)September 5, 2022
Actual (reported)December 15, 2023
Actual (reported)December 15, 2023
Actual (reported)Distribution of PVWMH
Maximal distance between the outer PVWMH border and the border of the lateral ventricle (on the axis oriented at 90° to the border of the ventricle)
Base line, Day 0
Distribution of PVWMH - total PVWMH extent.
The sum of the PVWMH measurements around the four ventricles horns (i.e. bilateral anterior and posteriors horns) resulted in total PVWMH extent.
Base line, Day 0
Corpus callosum (CC) WMH
Distance between the border of the third ventricle and the outer border of the WMH on the rostro-caudal axis, resulting in anterior and posterior CC-PVWMH extent measurements.
Base line, Day 0
Corpus callosum (CC) WMH - total CC-PVWMH extent.
The sum of the anterior and posterior CC-PVWMH measurements resulted in the total CC-PVWMH extent.
Base line, Day 0
Ratios
Calcul of posterior/anterior ratios for both the PVWMH and CC-PVWMH
base line, day 0
Patient with cerebral amyloid angiopathy
Patients with hypertensive arteriopathy
None, pure observational study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022
CHU de Nîmes
Nîmes, 30029, France
Deasy L, Laurent-Chabalier S, Wacongne A, Parvu T, Mura T, Thouvenot E, Renard D. Diagnostic Accuracy of Posterior/Anterior Periventricular WMH Ratio to Differentiate CAA From Hypertensive Arteriopathy. Stroke. 2024 Aug;55(8):2086-2093. doi: 10.1161/STROKEAHA.123.046379. Epub 2024 Jun 26.
Anissa MEGZARI
Centre Hospitalier Universitaire de Nīmes
315 participants (actual enrollment reported by the registry).
First Submitted
August 2, 2022
First Posted
August 4, 2022
Study Start
September 5, 2022
Actual (reported)Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies
Anterior PVWMH
Comparison of anterior PVWMH between CAA group and HA group.
Base line, Day 0
Posterior PVWMH
Comparison of posterior PVWMH between CAA group and HA group.
Base line, Day 0
Total PVWMH
Comparison of total PVWMH between CAA group and HA group.
Base line, Day 0
Posterior/anterior PVWMH ratio
Comparison of the posterior/anterior PVWMH ratio between CAA and HA groups.
Base line, Day 0
anterior CC-PVWMH
Comparison of anterior CC-PVWMH between CAA group and HA group.
Base line, Day 0
Posterior CC-PVWMH
Comparison of posterior CC-PVWMH between CAA group and HA group.
Base line, Day 0
Total PVWMH and posterior/anterior CC-PVWMH ratio
Comparison of total PVWMH and posterior/anterior CC-PVWMH ratio between CAA group and HA group.
Base line, Day 0
Contact the study team to confirm eligibility.
Primary Completion
December 15, 2023
Actual (reported)Study Completion
December 15, 2023
Actual (reported)Last Updated
December 4, 2025
Record last verified: 2024-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: